Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
TVS Srichakra Limited - Updates

2018-07-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TVSSRICHAK 509243

2
SBI, HPCL, IOC, Cipla, Dr Reddy’s, Bosch results

2018-05-21 thehindubusinessline
Close to 60 companies including Andhra Bank, Allcargo, Bata India, Batliboi, Ballarpur, Bemco Hydraulics, Bosch, Bharat Forge, Capital Trust, CARE, Cipla, Dr Reddy’s Laboratories, GE Power, Future Consumer, HPCL, Igarashi Motors, IOC, Jamna Auto, L&T Technology, Minda Industries, SBI, Sonata Soft, Sundaram Clayton, Symphony, TVS Srichakra, Triveni Turbine and VIP Industries will declare their quarterly and full-year results for the period ended March 2018 on Tuesday.
TRITURBINE ENKEIWHEL 500008 BEMHY MINDAIND 532539 532418 533477 ARJQY AMARAJABAT 533655 BATAINDIA TVSSRICHAK 511505 CAPITALT 509243 522650 500493 500043 BHARATFORG ANDHRABANK

0
TVS Srichakra Limited - Trading Window

2018-05-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TVSSRICHAK 509243

3
These 20 evergreen companies rising star stocks are your best bet to make a multibagger portfolio

2018-04-27 moneycontrol
Return-hungry investors are always on the lookout for stocks that can offer value and at the same time promise future growth which remains elusive in most of the companies that have rallied in the past year.
500825 519552 532809 FNXBY AVANTI FSL BRTQY 512573 519600 CCL PIDILITIND TVSSRICHAK PDLTY HERITGFOOD 509243 FINCABLES BRITANNIA 500331 500144

0
TVS Srichakra Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TVSSRICHAK 509243

0
TVS Srichakra Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TVSSRICHAK 509243

0
Tyre stocks rally: Balkrishna Ind jumps 6%, MRF hits record high, Apollo Tyres hits 52-week high

2018-04-03 moneycontrol
Despite the Indian equity market trading almost flat on Tuesday afternoon with the Nifty shedding 8 points at 10,203 mark and the Sensex was down 15 points or 0.05 percent, tyre stocks were in focus with MRF jumping 3.47 percent and hitting a record high of Rs 75,612 per scrip on the NSE.
BALKRISIND TVSSRICHAK 500877 APOLLOTYRE 509243 AYRQY 502355

0
Tyre stocks gain on falling rubber prices

2018-04-03 thehindubusinessline
Tyre stocks gained on falling rubber prices. Shares of tyre makers Apollo Tyres Ltd and TVS Srichakra Ltd were up over 2 per cent each in the morning trade.
TVSSRICHAK 500877 APOLLOTYRE 509243 AYRQY

0
TVS Srichakra Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TVSSRICHAK 509243

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...